Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 27, 2025 06:59 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update
February 12, 2025 06:50 ET | Source: Aclaris Therapeutics, Inc.

New Publication Highlights Unique Properties of ATI-2138, a Potent and Selective Inhibitor of ITK and JAK3

New Publication Highlights Unique Properties of ATI-2138, a Potent and Selective Inhibitor of ITK and JAK3
January 30, 2025 16:01 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics Announces Formation of New Scientific Advisory Board

Aclaris Therapeutics announces formation of new scientific advisory board
January 06, 2025 16:30 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
December 03, 2024 16:30 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
November 26, 2024 16:30 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference

Aclaris Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference
November 18, 2024 08:10 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics Announces $80 Million Private Placement

Aclaris Therapeutics Announces $80 Million Private Placement
November 18, 2024 08:10 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline

Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline
November 06, 2024 07:00 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update

Aclaris Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update
September 17, 2024 07:00 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Treatment of Moderate to Severe Atopic Dermatitis

Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Trea